Debiopharm’s Post

WEBINAR INVITE: Revolutionizing Novel Drug Design with AIDDISON™ Date: June 21, 2023 Time: 9:00 AM EST We are delighted to invite you to a webinar where we will explore how AI and ML-based predictive models are revolutionizing the field of novel drug design. The webinar will focus on AIDDISON™, an AI-powered drug discovery platform that integrates models from ML to identify novel hits. By attending this webinar, you will learn: 1. How AI and ML-based predictive models are used in preclinical research 2. Operational insights and challenges of predictive models in drug discovery 3. How AIDDISON™ integrates ML-based models to enable efficient drug discovery. 4. Examples of how to use predictive models for novel hit identification Join us in this exciting discussion to discover how ML and AI-based models are changing the game in drug discovery! tps://https://lnkd.in/e4s84HUH #ai #webinar #drugdiscovery #ml

I recently read a Q&A with Alister Campbell, VP of Science at Dotmatics. He discusses how AI is revolutionising drug discovery by cutting development time and costs. The AI platform Luma (developed by Dotmatics) enhances data integration and analysis, proving beneficial for companies like Addex Therapeutics. Alister also talks about the important challenges such as data quality & model transparency as well as anticipating significant advancements in AI technology. Interesting insights written by Andrew Humphreys! #AI #drugdiscovery #pharmatech #biotech #healthtech #innovation #datascience #clinicaltrials #artificialintelligence #pharmaresearch

𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐀𝐈 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐝𝐞𝐬𝐢𝐠𝐧𝐢𝐧𝐠 𝐧𝐞𝐰 𝐝𝐫𝐮𝐠𝐬 𝐚𝐥𝐥 𝐨𝐧 𝐢𝐭𝐬 𝐨𝐰𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐧𝐞𝐚𝐫 𝐟𝐮𝐭𝐮𝐫𝐞 🙌 At the forefront of pharmaceutical innovation, generative AI is set to transform how we discover and design new drugs. Recently at Eli Lilly and Company, experiments led by Chief Information and Digital Officer Diogo Rau revealed the potential of AI in accelerating drug discovery. Utilizing generative AI, Lilly has been able to sift through millions of molecules, achieving in mere minutes what would traditionally take a year in the lab. The initial skepticism from executives about AI's ability to contribute real value was met with surprising feedback from scientists. They found the AI-generated molecular designs, albeit unconventional, intriguing and potentially viable for drug development. This marks a significant shift in how we approach pharmaceutical research, highlighting AI’s role in uncovering novel pathways and designs that human researchers might not consider. This shift began gaining clarity back in 2021 with DeepMind’s AlphaFold, which demonstrated the power of AI in predicting protein structures from amino acid sequences, a foundational process in drug design. Such developments suggest that the full potential of AI in medicine is just beginning to be tapped. As we stand on the brink of an era where AI might entirely generate medicines, the implications for the pharmaceutical industry and medical science are profound. This technology not only speeds up the discovery process but also enhances creative problem-solving, paving the way for groundbreaking treatments. At Medvolt, we are also harnessing the power of generative AI, alongside other large language models (LLMs) and deep learning technologies, through our innovative platform 𝐌𝐞𝐝𝐆𝐫𝐚𝐩𝐡. 𝐌𝐞𝐝𝐆𝐫𝐚𝐩𝐡 is specifically designed to pioneer novel drug discoveries, contributing to cutting-edge developments in the field. Our commitment to integrating advanced AI tools reflects our dedication to leading the charge in transformative healthcare solutions. 𝐅𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐢𝐟 𝐲𝐨𝐮 𝐡𝐚𝐯𝐞 𝐚𝐧𝐲 𝐢𝐧𝐪𝐮𝐢𝐫𝐢𝐞𝐬 𝐨𝐫 𝐫𝐞𝐪𝐮𝐢𝐫𝐞 𝐚 𝐝𝐞𝐦𝐨𝐧𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧. 𝐖𝐞'𝐫𝐞 𝐡𝐞𝐫𝐞 𝐭𝐨 𝐚𝐬𝐬𝐢𝐬𝐭 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐜𝐥𝐚𝐫𝐢𝐭𝐲. Email: contact@medvolt.ai Website: https://www.medvolt.ai #AI #ML #Drug #Discovery #Innovation #Pharmaceutical #Development #drugdiscovery #llm #oncology #infectiousdiseases #encoders #cancer #genai

Curious how AI can be used to help speed up the drug development process? Insilico Medicine has provided a great test case that is worth following closely. The NYC-based company’s AI platform, Pharma.AI, identified a ground-breaking drug candidate for idiopathic pulmonary fibrosis in just 18 months, a process that traditionally takes six years and over $400 million. By leveraging deep learning at every step, from target identification to predicting clinical trial outcomes, they've accelerated the drug discovery process exponentially. Now, their first AI-driven candidate has entered Phase 2 trials, marking a major milestone in the field of AI-accelerated drug development. The Phase II study is expected to take several months, and we are eager to hear about the results, and to see what other companies can use AI to speed up the drug development process. We love working with cutting edge companies like these who intrinsically understand the value technology can bring to clinical trial efficiency. Let's talk! #AI #DrugDiscovery #ClinicalTrials #TheFutureisHere

🌟 A look back on our most read 3decision blog article of the year! 🌟 🧬 Discover how Alphafold, the revolutionary AI system, is revolutionizing the field, accelerating drug development, and unlocking new possibilities in medicine; thanks to in our article: "The impact of AlphaFold in Drug Discovery and emerging ML-Methods" 💡 👉 Read now our captivating article that captured the attention of thousands, https://bit.ly/481PIXb #3decisionBlog #DrugDiscovery #Alphafold #MLmethods #ArtificialIntelligence #Discngine

#AI across Industries: Part 1 - Healthcare and Life Sciences Generative AI enhances automation, improves efficiency, and creates new opportunities for innovation. For Healthcare and Life Sciences, Generative AI is: 🩺 Being used to assist in early diagnosis by analyzing medical images, such as X-rays and MRIs, for faster and more accurate detection of conditions like cancer 💡 Aiding in personalized treatment planning by analyzing patient data 💊 Accelerating drug discovery in the pharmaceutical sector by analyzing data sets on side effects and clinical study results, potentially reducing the time-to-market for new drugs Engage with us to explore the forefront of innovation! If you found these insights valuable, give this post a thumbs up and stay tuned for more updates. Your thoughts and discussions fuel our journey—let's drive the future together. #AIInnovation

If you want to stay in the loop with the latest news in the healthcare analytics space from the last two weeks, this post is for you. At Decode Health, we’re building for the future of healthcare, empowering the healthcare industry to implement & leverage AI, Machine Learning & Analytics across their R&D process. Below are a few of the articles that our team has been reading & talking about; 1. Machine learning biotech Generate:Biomedicines raises $273 million in a rare successful late-stage round from investors at Amgen & the VC arm of NVIDIA. [via STAT ] https://lnkd.in/gE4uTNfm 2. Decode Health’s CEO, Chase Spurlock, to speak at the upcoming MSMilan 2023 Conference from October 11-13, 2023, highlighting recent research findings from their partnership with Quest Diagnostics 3. “The fact that 90 percent of drugs fail in the clinic tells us that there’s room for improvement. It’s a really complex system” says Recursion CEO Chris Gibson.  AI-discovered drugs will be for sale sooner than you think. [via Vox] https://lnkd.in/dTUiw-Xf 4. “AI has the potential to improve and reinvent the way our business operates” according to Sanofi CEO Paul Hudson. [via STAT] https://lnkd.in/eRDcQ5BM 5. The upfront investment needed to make artificial intelligence (AI) and machine learning (ML) viable in the pharmaceutical sector will be worth it” according to Bryan Abney of the Syner-G BioPharma Group.  https://lnkd.in/gVeXuGJY

AI Revolutionizing Biopharma: Transforming the Landscape 🎓Artificial Intelligence (AI) is rapidly reshaping the biopharma industry, revolutionizing drug discovery, clinical trials, and personalized medicine. Leading companies like NVIDIA and Globant are harnessing the power of AI to drive innovation and accelerate breakthroughs. Recent research articles published in Science Direct and Cell are highlighting the significant impact of AI in biopharma, showcasing its potential to transform the landscape. ✍️https://lnkd.in/etCD9sjg ✍️https://lnkd.in/ed6nsvua 💡AI in Drug Discovery: AI algorithms analyze vast amounts of data to identify potential drug candidates, significantly reducing the time and cost involved in traditional methods. Companies utilize AI to predict drug-target interactions, enabling the identification of novel therapeutic targets. Latest reports underscore how AI-driven drug discovery platforms have successfully identified promising candidates for various diseases. 💡AI in Clinical Trials: AI streamlines clinical trial processes by optimizing patient recruitment, monitoring, and data analysis. By deploying novel AI solutions to identify suitable patients for trials, enhancing efficiency and reducing costs, recently developed AI-powered predictive models improve patient selection and trial outcomes, leading to faster drug approvals. 🤞AI in Personalized Medicine: AI enables the development of personalized treatment plans by analyzing patient data and genetic profiles. By utilizing AI to identify biomarkers and predict patient response to specific therapies or how AI algorithms have improved the accuracy of personalized medicine, companies are now tailoring treatments to individual patients and improving overall outcomes. 🎬GlobalReach BI’s latest launch of an OpenAI-enabled SPRING platform was presented by our Founder and CEO Yamina Hakem at recent scientific congresses. By leveraging AI and our team’s extensive expertise we provide companies with a customizable solution to manage the growing volume and complexity of Competitive Insights, while integrating their brand and portfolio. https://lnkd.in/e5kTrP69 #pharma #biopharma #drugdiscovery #researchanddevelopment #lifesciences #healthtech #biotech #medtech #healthcare #precisionmedicine #precisionhealth #virtualhealth #telehealth #innovation #artificialintelligence #technology #deeptech #leadership #clinicaltrials #research #scienceandtechnology

#AI in the Clinic: Supporting #Drug Development AI's ability to interpret data and learn from it is transforming how we approach #research and innovation in the Life Sciences industry. It is revolutionizing drug discovery, making it more efficient and cost-effective. One key area where AI shines is in the optimization of clinical trials. By leveraging advanced imaging and AI-driven biomarkers, we can identify treatment efficacy earlier and with greater precision. This not only accelerates the development process but also enhances #patient outcomes. At IAG, IMAGE ANALYSIS GROUP, we're passionate about harnessing the power of AI to drive meaningful advancements in #healthcare. With our expertise in AI-driven methodologies and innovative imaging technologies, we're proud to partner with biotech and pharma companies to unlock the full potential of AI in drug development. Ready to embark on your AI initiative? Reach out to our expert team at IAG to explore how AI can supercharge your drug development efforts and bring life-saving treatments to market faster. #AIinHealthcare #Machinelearning #DrugDevelopment #Innovation #ArtificialIntelligence #lifesciences #biotechnologyindustry #clinicaltrials

Transforming Drug Discovery with AI: 🧬🤖 We're harnessing AI to revolutionize drug discovery and clinical trials. Our commitment to incorporating advanced machine learning technologies helps us to better predict drug behaviors, enhancing both efficacy and safety. This approach not only speeds up the discovery process but also ensures higher precision in targeting diseases. Interested in how AI is shaping the future of pharma? Let’s connect to explore groundbreaking career opportunities in clinical development at Amgen! #AmgenInnovation #clinicaldevelopment